Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2015

View Archived Issues

Biophysical mechanisms causing susceptibility to tinnitus identified

GW Pharmaceuticals reports PoC data for cannabidiol in schizophrenia

BriaCell to develop companion diagnostic to BriaVax

Daiichi Sankyo and Translational Sciences to develop thrombus dissolving agent

NecroX-7 reduces renal ischemia-reperfusion injury in vivo

QRLS1 mutations identified as a cause of infantile mitochondrial disease

Opdivo receives FDA breakthrough therapy designation for renal cell carcinoma

Intra-Cellular Therapies reports topline data from phase III trial of ITI-007

Nuvo Research to split into commercial healthcare and biotech development companies

Malaria vaccine shows promising preliminary safety results

ClearLight Diagnostics licenses Stanford IP for tissue processing and imaging technologies

Contextual Genomics and National Cancer Institute of Canada enter collaboration

Genfit develops circulating miRNA diagnostic kit for NASH

Interim update from Chinese trial of BTI-320 in prediabetic patients

InSite Vision enters merger agreement with Sun Pharma, terminates QLT merger agreement

Researchers identify novel mutation in GBE1 gene in a GSD-IV patient

Novo Nordisk reports stable glucagon analogues

AbbVie plans to proceed to phase III evaluation of elagolix

Bristol-Myers Squibb reports HIV integrase inhibitor macrocycles

BioRestorative collaborates with University of Pennsylvania to research brown adipose biology

Chinese team presents anti-HCV agents

Amgen and Xencor collaborate in cancer immunotherapy and inflammation

Japan Tobacco presents mPGES-1 inhibitors

Trulicity launched in Japan

Edison Pharmaceuticals develops agents for pervasive developmental disorders

Viamet's VT-1129 obtains FDA's QIDP designation for cryptococcal meningitis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...